Diprofol emulsion for injections 2% 50 ml. №1 vial


Manufacturer: Belgium

For induction of intravenous anesthesia for maintenance of General anesthesia. To provide a sedative effect during artificial lung ventilation, as well as for sedation with preservation of consciousness during surgical and diagnostic procedures.



Diprofol Storage
active substance: рropofol;

1 ml of emulsion contains 20 mg of propofol;

Diprofol Excipients: soybean oil, egg phospholipid, glycerin, sodium hydroxide, disodium edetate, water for injections.

Diprofol Dosage form
Emulsion for infusions.

Main physical and chemical properties: white or almost white homogeneous emulsion, practically free of solid particles and large oil droplets. During prolonged settling, a slight stratification of the emulsion is possible.

Pharmacotherapeutic group
Anesthetics. Means for general anesthesia.

ATX code N01A X10.

Pharmacological properties


Mechanism of action

Propofol (2,6-diisopropylphenol) is a general short-acting anesthetic with a rapid onset of effect for approximately 30 seconds. Recovery from anesthesia is usually rapid. The mechanism of action, as for other drugs for general anesthesia, is insufficiently studied. However, it is believed that propofol has sedative and narcotic effects by positively affecting the inhibitory function of the neurotransmitter GABA (gamma-aminobutyric acid) by facilitating the interaction of the latter with ligand-activated GABA receptors.

Pharmacodynamic properties

Typically, propofol 2% is used to induce and maintain anesthesia to reduce mean blood pressure and slight changes in heart rate. However, hemodynamic parameters under normal conditions remain relatively stable during maintenance of anesthesia, and the number of cases of adverse hemodynamic reactions is small.

Although respiratory depression may develop after administration of 2% propofol, any reactions are qualitatively similar to those with other intravenous anesthetic agents and are easily corrected in clinical practice.

Propofol 2% reduces cerebral circulation, intracranial pressure and brain metabolism. The decrease in intracranial pressure is more pronounced in patients with initial elevated intracranial pressure.

As a means of general short-term anesthesia, the drug is administered intravenously for:

induction and maintenance of general anesthesia in adults and children> 3 years of age;
sedation during diagnostic and surgical procedures, alone or in combination with drugs for local or regional anesthesia, in adults and children> 3 years of age;
sedation of patients> 16 years of age undergoing artificial lung ventilation in the intensive care unit (ICU).

Hypersensitivity to the active substance or to any of the excipients.

Children under 3 years (for induction and maintenance of general anesthesia).

Diprofol® EDTA 2% contains soybean oil and is not intended for use in patients with hypersensitivity to peanuts or soybeans.

Diprofol® EDTA 2% should not be used for sedation in patients ≤ 16 years of age in the intensive care unit (see section 4.4).